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Abstract
Background: Currently, several fatigue measurement instruments are available to evaluate and measure cancer-
related fatigue. Amongst them, Multidimensional Fatigue Syndrome Inventory-Short Form (MFSI-SF) is a self-
reported instrument and a multidimensional scale that aims to capture the global, somatic, affective, cognitive and
behavioural symptoms of fatigue. This study examines the psychometric properties and measurement equivalence
of the English and Chinese versions of MFSI-SF in breast cancer and lymphoma patients in Singapore.
Methods: Patients were recruited from National Cancer Centre Singapore. Validity, reliability and responsiveness of
MFSI-SF were evaluated in this study. Convergent validity was evaluated by correlating total and subscales of MFSI-
SF to known related constructs in EORTC QLQ-C30. Known group validity was assessed based on patients’ cancer
stage, pain, insomnia and depression symptoms. Reliability was evaluated by Cronbach’s α. Responsiveness analyses
were performed with patients who have undergone at least one cycle of chemotherapy. Multiple regression was
used to compare the total and subscale scores of MSFI-SF between the two language versions.
Results: Data from 246 (160 English and 86 Chinese version) breast cancer and lymphoma patients were included in
the study. Moderate to high correlations were observed between correlated MFSI-SF subscales and EORTC QLQ-C30
domains (|r| = 0.524 to 0.774) except for a poor correlation (r = 0.394) observed between MFSI-SF vigour subscale and
EORTC QLQ-C30 role functioning subscale. Total MFSI-SF scores could differentiate between patients with higher
depression, pain and insomnia status. Internal consistency of MFSI-SF was also high (α = 0.749 to 0.944). Moderate
correlation was observed between change in total MFSI-SF score and change in fatigue symptom scale score and
global QoL score on EORTC QLQ-C30 (|r| = 0.478 and 0.404 respectively). Poor correlations were observed between
change in scores of hypothesised subscales (|r| = 0.202 to 0.361) except for a moderate correlation between change in
MFSI-SF emotional fatigue score and change in EORTC QLQ-C30 emotional functioning domain score. Measurement
equivalence was established for all subscales and total MFSI-SF score except for the emotional and vigour subscales.
(Continued on next page)
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Conclusions: This study supports the use of MFSI-SF as a reasonably valid scale with good internal consistency for
measuring fatigue levels in the Singapore cancer population.
Keywords: Psychometrics, Cancer, Fatigue, Health-related quality of life, Outcome assessment (health care)
Background
Cancer-related fatigue (CRF) has been reported as
one of the most distressing symptoms of cancer and
cancer treatments, and the prevalence ranges from
25% to 99% depending on different patient demo-
graphics, types of cancer and treatment received [1].
CRF has also been shown to be more severe and de-
bilitating than normal fatigue experienced by people
without cancer [2, 3]. However, CRF is often under-
mined and underdiagnosed by caregivers and clini-
cians due to the subjective nature of fatigue and the
lack of diagnostic framework. Hence, there is a need
for well-validated instruments to measure fatigue in
order to facilitate diagnosis and management.
Currently, several fatigue measurement instruments
are available to evaluate and measure CRF [1].
Amongst them, Multidimensional Fatigue Syndrome
Inventory-Short Form (MFSI-SF) is a self-reported in-
strument and a multidimensional scale that aims to
capture the global, somatic, affective, cognitive and
behavioural symptoms of fatigue [4]. The psychomet-
ric properties of the English version of MFSI-SF was
previously validated in the United States, and its fac-
tor structure was confirmed in majority breast cancer
patients [5]. A Chinese version of the MFSI-SF has
also been examined for its psychometric properties in
Taiwan [6]. However, cross cultural adaptations of
Health-Related Quality of Life instruments could pos-
sibly affect the validity of a questionnaire [7]. Given
Singapore’s unique multi-ethnic demographic, it is im-
portant to evaluate the psychometric properties of the
English and Chinese versions of the MFSI-SF within
the Asian cancer population in Singapore.
To ensure that MFSI-SF is a valid and reliable
scale for use in the Singapore cancer population, the
primary objective of this study is to evaluate the psy-
chometric properties (validity, reliability and respon-
siveness) of both the English and Chinese versions of
the MFSI-SF. Furthermore, we also aim to determine
the measurement equivalence between the two lan-
guage versions.
Methods
Subjects and study design
This was a single-center, prospective study conducted at
the outpatient clinics of the National Cancer Centre
Singapore (NCCS) between 2014 and 2017. In this study,
patients recruited 1) had a diagnosis of breast cancer or
lymphoma 2) were at least 21 years old, 3) on or sched-
uled to receive chemotherapy, 4) ambulatory in nature
[defined as an Eastern Cooperative Oncology Group
(ECOG) performance status1 score of 0 or 1], 5) able to
speak English or Chinese, and 6) were willing to give
their informed consent [8]. The patients were excluded
from the study if they were at the last time point of
chemotherapy, have breast cancer or lymphoma as a
secondary metastasis and physically or mentally in-
capable of giving written consent. This study was ap-
proved by SingHealth Institutional Ethics Review
Board before commencement.
Study procedure
Patients were requested to self-administer either the
English or Chinese version of two questionnaires –
MFSI-SF and the European Organisation for Research
and Treatment of Cancer Quality of Life Core Question-
naire 30 (EORTC-QLQ-C30) in a 30-min period (T1).
Choice of the version of the questionnaire to be admin-
istered was based on patient’s language preference and
proficiency. Subsequently, the same version of the ques-
tionnaire was administered to the patients at their next
follow up appointment (T2). At the time of follow-up,
patients must have undergone at least one round of
chemotherapy after T1.
Psychometric assessments of CRF
MFSI-SF
The MFSI-SF is a 30-item multidimensional tool used
to measure CRF experienced in the past week [5]. It
consists of 5 empirically derived subscales: general,
physical, emotional, mental and vigour. For each item,
patients indicated their response on a 5-point Likert
scale from 0 (“not at all”) to 4 (“extremely”). Scores
on the individual subscales were then tabulated by
summing the item scores for each subscale. Each sub-
scale score ranges from 0 to 24. The Total MSFI-SF
score was tabulated by adding the general, physical,
emotional and mental subscale scores and subtracting
vigour subscale score [5]. Total MFSI-SF score ranges
from − 24 to 96 with a higher score indicating higher
levels of CRF experienced by the patient. The transla-
tion process closely followed the guidelines stipulated
by the Translation and Cultural Adaptation-Principles
of Good practice [9]. The English version of MFSI-SF
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was first translated to the Chinese version by two co-
investigators (within the research group) who are
proficient in both languages, followed by backward-
translation by two other trained bilingual investigators
independently. Any discrepancies with translation
were resolved through discussion. After proof reading
of the final questionnaire, a pilot study was conducted
in a small group of cancer patients to test for under-
standing. The questionnaire was then further revised
based on patients’ feedback to obtain the final version
used in this study.
EORTC QLQ-C30
The EORTC QLQ-C30 is a cancer specific tool to as-
sess patients’ health related quality of life (HRQoL) in
the past week [10]. The questionnaire consists of 30
items that includes a global QoL scale, five functional
scales (physical, role, emotional, cognitive and social);
three symptom scales (fatigue, nausea/vomiting and
pain); six single items (dyspnea, insomnia, appetite
loss, constipation, diarrhoea and financial stability).
All EORTC QLQ-C30 items are rated on a four-point
likert scale (‘not at all = 1′, ‘a little = 2′, ‘quite a bit =
3′ and ‘very much = 4′) except the two items asses-
sing global QoL that uses a seven-point scale. Raw
scores were linearly transformed to a 0 to 100 scale,
where a higher score represent better functioning,
better QoL or worse symptoms respectively. For this
study, the domains in EORTC QLQ-C30 were used to
establish the validity of MFSI-SF as both the English
and Chinese version of the EORTC QLQ-C30 were
previously validated in Singapore [11–13].
Statistical analysis
SPSS statistics version 24 was used for all statistical ana-
lysis. Missing values from EORTC QLQ-C30 were man-
aged as stipulated in the scoring manual. Patients with
incomplete responses from MFSI-SF were excluded from
analysis. Descriptive statistics were used for demograph-
ics and clinical characteristics of the patients. Baseline
characteristics of the English and Chinese population
were also compared. Independent samples t-test was
used for continuous data that was normally distributed,
whereas Mann-Whitney U test was used for data that
was not normally distributed. Categorical data were
compared using Chi-square tests. Significance tests were
conducted at a significance level of 0.05 (two-tailed). To
examine the psychometric properties, the validity, reli-
ability and responsiveness of MFSI-SF were evaluated.
Data collected from patients at T1 were used to examine
the validity, reliability and measurement equivalence of
the MFSI-SF. Patients who had data at both T1 and T2
were included for responsiveness analyses.
Validity
To assess whether MFSI-SF is a valid measure for pa-
tient’s fatigue level, a correlation analysis with EORTC
QLQ-C30 was done. EORTC QLQ-C30 was chosen as
the reference for validation as it has been well-validated
in both the local and international population [10–12,
14–18]. Spearman correlation was used for all correl-
ation analysis as data obtained cannot be approximated
to a normal distribution. A statistically significant correl-
ation was indicated by a P < 0.05. Correlation values of
< 0.4 are poor; 0.4–0.7 are moderate and > 0.7 are strong
correlations [19].
To evaluate the construct validity of MFSI-SF, we
compared total and subscale MFSI-SF scores to their
known related construct in EORTC QLQ-C30. As
studies have shown that CRF usually coexists with
symptoms of pain, insomnia, and dyspnoea [20–22],
we hypothesised that total MFSI-SF score would have
a moderate to strong (|r| ≥ 0.4) correlation with the
pain symptom subscale as well as the insomnia and
dyspnoea items on EORTC QLQ-C30. Moreover, CRF
is closely associated with patients’ QoL [23, 24].
Hence, we hypothesised that the global QoL scale on
the EORTC QLQ-C30 would correlate with total
MFSI-SF score. For the subscales of MFSI-SF, we
hypothesised that the physical, emotional, mental and
vigour subscale on MFSI-SF would correlate with the
physical, emotional, cognitive and role functioning
subscales on EORTC QLQ-C30. Lastly, total and sub-
scale scores of MFSI-SF would correlate with the fa-
tigue symptom scale on EORTC QLQ-C30. All
hypothesised correlations were expected to be moder-
ate to strong (|r| ≥ 0.4).
Divergent validity was assessed to evaluate whether
scales in EORTC QLQ-C30 not associated with CRF
would be poorly correlated with MFSI-SF scores. We
hypothesised that total and subscale MFSI-SF score
would be poorly correlated to constipation and diar-
rhoea items on EORTC QLQ_C30 (|r| < 0.4).
Known group validity was performed to assess
MFSI-SF’s ability to differentiate between differing
groups known to have characteristics that affect fa-
tigue levels. Studies have shown that CRF is associ-
ated with more advanced cancer staging [24, 25].
Hence, we hypothesised that patients with more ad-
vanced cancer stage (I-II vs. III-IV) would have a
higher MFSI-SF total score. Furthermore, CRF is asso-
ciated with depression, insomnia and pain [20–22,
25–27]. Hence, we hypothesised that patients with a
higher score on EORTC QLQ-C30 item 24 “Did you
feel depressed”, item 11 “Have you had trouble sleep-
ing” and item 9 “Have you had pain” (1–2 vs. 3–4)
would have a higher MFSI-SF score. Based on the
established Minimal Clinically Important Difference
Chan et al. Health and Quality of Life Outcomes  (2018) 16:20 Page 3 of 14
(MCID) of MFSI-SF (4.50–10.79 points), we hypothe-
sized that a score difference of ≥10 points between
the groups represent a clinically significant difference
[28]. To evaluate the statistical significance, Mann-
Whitney U tests were used to compare the scores be-
tween the known groups.
Reliability
Internal consistency of MFSI-SF was evaluated using
Cronbach’s alpha coefficient (α). An α value of above 0.7
was regarded as having satisfactory consistency [29]. An
item-to-subscale correlation analysis was also performed
to identify problematic or inconsistent items in the re-
spective MFSI-SF subscale. Correction overlap was ap-
plied by calculating the corrected item-to-subscale
correlation for each item after removing its contribution
to subscale scores. Any items with a correlated item-to-
scale correlation of more than 0.3 were considered
acceptable.
Responsiveness
Responsiveness refers to the ability of a scale to de-
tect changes over time in the construct to be mea-
sured [30]. In this case, responsiveness of MFSI-SF
refers to the ability of MFSI-SF to detect changes in
patient’s fatigue level following known interventions.
Patients were followed-up after they have undergone
at least one or more chemotherapy (T2) as studies
showed that patient’s fatigue level changes with con-
secutive cycles of chemotherapy [31, 32]. The change
in EORTC QLQ-C30 domain scores was used as the
reference to evaluate the responsiveness of MFSI-SF
as the responsiveness of EORTC QLQ-C30 was dem-
onstrated in previous studies [17, 33].
Treating responsiveness as a longitudinal aspect of val-
idity, we used the criterion approach to evaluate respon-
siveness. We compared the change in total and
subscales MFSI-SF scores to the change in scores of
known related constructs in EORTC QLQ-C30. We
hypothesised that an improvement in total MFSI-SF
score (i.e. a lower score) would correspond to lower
scores on the fatigue, pain, dyspnoea and insomnia
symptom scale on the EORTC QLQ-C30. We also
hypothesised that an improvement in total MFSI-SF
score would correspond to an improvement in global
QoL score on the EORTC QLQ-C30.
For the change in subscales score of MFSI-SF, we
hypothesised that an improvement in physical, emo-
tional, mental and vigour subscales score on MFSI-SF
would correspond to an improvement in physical, emo-
tional, cognitive and role functioning score on EORTC
QLQ-C30 respectively. In addition, improvements in
total and subscale scores of MFSI-SF were hypothesised
to correlate with improvements in the fatigue symptom
scale on EORTC QLQ-C30. All related correlations were
hypothesised to be moderate to strong (|r| ≥ 0.4).
In addition to establishing the longitudinal validity
(responsiveness) using the construct approach, the
ability of MFSI-SF to detect clinically significant
changes in scores was also evaluated. Based on the
MCID established, a score difference of ≥10 between
T1 and T2 was regarded as a clinically significant
change [28].
Measurement equivalence
Measurement equivalence evaluates the similarity in
psychometric properties between the English and
Chinese version. Using the methodology for assessing
therapeutic equivalence in clinical trials, the 95% CIs
of MFSI-SF total and subscales score differences were
compared with predefined equivalence margins to de-
termine whether differences in scores were clinically
important [34, 35]. As score differences between the
Chinese and English versions could be due to under-
lying differences in baseline characteristics, a univari-
ate analysis was first performed to single out variables
that were statistically significant between patients
completing the Chinese and English version of the
MFSI-SF. Subsequently, multiple regression analysis
was performed to tabulate the 95% CIs of the score
differences after adjusting for these variables. Equiva-
lence was established if the 95% CIs of the adjusted
mean differences fell within predefined equivalence
margin of ±0.5 [35, 36].
Results
Demographic characteristics
255 patients were recruited in the study. Out of 255 pa-
tients, 8 patients (3.1%) had incomplete responses to
MFSI-SF and were excluded from the study, 1 patient
(0.4%) withdrew from the study.
A total of 246 breast cancer and lymphoma patients
were included for analysis. One hundred and sixty pa-
tients (65.0%) completed the English version of the
MFSI-SF while 86 patients (35.0%) completed the Chin-
ese version of MFSI-SF (Table 1). There were 6 missing
responses (0.08%) for 6 different items on the EORTC
QLQ-C30 and they were managed as stipulated in the
scoring manual. The six missing responses were from
EORTC QLQ-C30 items 1, 2, 3, 11, 17, 24. Majority of
the patients were females (93.5%), Chinese (80.5%),
breast cancer patients (91.5%), married (73.6%) and have
an ECOG performance status of 0 (89.8%). Statistically
significant differences were observed for age, race, edu-
cation levels, ECOG status and menopausal status be-
tween patients who completed the English and Chinese
version of the MFSI-SF.
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Table 1 Baseline demographic and clinical information of patients
Total (N = 246) English Version (n = 160) Chinese Version (n = 86) P-value
Demographic information
Age, mean (± SD) 53.4 (±10.0) 51.2 (± 10.3) 57.4 (±8.0) < 0.001#
Gender, n (%) 0.192
Female 230 (93.5) 152 (95.0) 78 (90.7)
Male 16 (6.5) 8 (5.0) 8 (9.3)
Race, n (%) < 0.001#
Chinese 198 (80.5) 114 (71.3) 84 (97.7)
Non-Chinese
Malay 26 (10.6) 26 (16.3) 0 (0.0)
Indians 12 (4.9) 12 (7.5) 0 (0.0)
Others 10 (4.1) 8 (5.0) 2 (2.3)
Marital Status, n (%)
Single 45 (18.3) 32 (20.0) 13 (15.1) 0.546
Married 181 (73.6) 116 (72.5) 65 (75.6)
Divorced 17 (6.9) 11 (6.9) 6 (7.0)
Widowed 3 (1.2) 1 (0.6) 2 (2.3)
Education, n (%) < 0.001#
Low Education 42 (17.1) 6 (3.8) 36 (41.9)
None 9 (3.7) 2 (1.3) 7 (8.1)
Primary 33 (13.4) 4 (2.5) 29 (33.7)
High Education 204 (82.9) 154 (96.3) 50 (58.1)
Secondary 111 (45.1) 73 (45.6) 38 (44.2)
Pre-University 45 (18.3) 37 (23.1) 8 (9.3)
Graduate and Above 48 (19.5) 44 (27.5) 4 (4.7)
Occupation, n (%) 0.097
Employed 130 (52.8) 93 (58.1) 37 (43.0)
Unemployed 90 (36.6) 53 (33.1) 37 (43.0)
Student 1 (0.4) 1 (0.6) 0 (0.0)
Retired 25 (10.2) 13 (8.1) 12 (14.0)
Clinical Information
ECOG, n (%) 0.030#
0 221 (89.8) 149 (93.1) 72 (83.7)
1 15 (6.1) 6 (3.8) 9 (10.5)
Missing 10 (4.1) 5 (3.1) 5 (5.8)
Menopausal status, n (%) < 0.001#
Pre-menopausal 98 (39.8) 79 (49.4) 19 (22.1)
Post-menopausal 129 (52.4) 71 (44.4) 58 (67.4)
Not Applicable 16 (6.5) 8 (5.0) 8 (9.3)
Missing 3 (1.2) 2 (1.3)
Cancer Diagnosis, n (%) 0.427
Breast 225 (91.5) 148 (92.5) 77 (89.5)
Lymphoma 21 (8.5) 12 (7.5) 9 (10.5)
Cancer Stage, n (%) 0.554
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Validity
Correlation coefficients can be found in Table 2 and
Additional file 1: Table S1. All hypothesised correl-
ation coefficients performed in the expected direction
and magnitude except for the correlation between the
vigour subscale and role functioning subscale, total
MFSI-SF score and EORTC QLQ-C30 pain symptom
score and insomnia item score. Based on the criteria
set for correlation coefficients interpretation, a
moderate correlation was observed between total
MFSI-SF score and EORTC QLQ-C30 global QoL
scale, fatigue symptom scale and dyspnoea item
scores (|r| = 0.419 to 0.667). A poor correlation was
observed between total MFSI-SF score and EORTC
QLQ-C30 pain symptom scale and insomnia symptom
item scores (|r| = 0.378 and 0.386 respectively). Cor-
relating MFSI-SF’s subscales, a high correlation was
observed between the emotional and mental fatigue
Table 1 Baseline demographic and clinical information of patients (Continued)
Total (N = 246) English Version (n = 160) Chinese Version (n = 86) P-value
I 34 (13.8) 26 (16.3) 8 (9.3)
II 134 (54.5) 87 (54.4) 47 (54.7)
III 50 (20.3) 31 (19.4) 19 (22.1)
IV 23 (9.3) 15 (9.4) 8 (9.3)
Unknown 5 (2.0) 1 (0.6) 4 (4.7)
Chemotherapy Regimen, n (%) 0.819
Anthracycline containing 132 (53.7) 85 (53.1) 47 (54.7)
Non-anthracycline containing 114 (46.3) 75 (46.9) 39 (45.3)
ECOG Eastern Cooperative Oncology Group, Pre-M pre-menopausal, Post-M post-menopausal
#Denotes statistically significant difference (P < 0.05)
Table 2 Spearman’s correlations between MFSI-SF subscales and EORTC QLQ-C30 domains
EORTC QLQ-C30 MFSI-SF
General Fatigue Physical Fatigue Emotional Fatigue Mental Fatigue Vigour Total Score
Functional
Physical − 0.501a − 0.524a − 0.404a − 0.347a 0.358a − 0.515a
Role − 0.507a − 0.397a − 0.412a − 0.390a 0.394a − 0.501a
Emotional − 0.581a − 0.492a − 0.774a − 0.482a 0.488a − 0.661a
Cognitive − 0.416a − 0.383a − 0.476a − 0.756a 0.324a − 0.519a
Social − 0.509a − 0.421a − 0.485a − 0.500a 0.478a − 0.591a
Global QOL
Global health status (GHS) − 0.559a − 0.533a − 0.492a − 0.436a 0.612a − 0.667a
Symptom scales
Fatigue 0.655a 0.537a 0.517a 0.451a − 0.463a 0.627a
Pain 0.374a 0.461a 0.367a 0.244a − 0.230a 0.378a
Symptom Items
Dyspnoea 0.410a 0.365a 0.363a 0.366a − 0.287a 0.419a
Insomnia 0.367a 0.398a 0.360a 0.319a − 0.234a 0.386a
Appetite loss 0.365a 0.378a 0.323a 0.232a − 0.380a 0.410a
Constipation 0.348a 0.265a 0.225a 0.206a − 0.267a 0.323a
Nausea & vomiting 0.254a 0.229a 0.218a 0.127b − 0.221a 0.272a
Diarrhoea 0.124 0.248a 0.113 0.211a − 0.089 0.176a
Financial Difficulties 0.392 0.364a 0.416a 0.324a − 0.378a 0.470a
MFSI-SF Multidimensional Fatigue Symptom Inventory - Short Form, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life
Core Questionnaire 30
Unmarked correlations were not significant at the 0.05 level
aCorrelation was significant at the 0.01 level (2-tailed)
bCorrelation was significant at the 0.05 level (2 tailed)
Bolded values indicate hypothesised correlations
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subscales of the MFSI-SF and the emotional and cog-
nitive functioning domains on the EORTC QLQ-C30
(r = − 0.774 and r = − 0.756, respectively). The physical
subscale had a moderate correlation with the EORTC
QLQ-C30 physical functioning domains (r = − 0.524)
and a poor correlation was observed between the
vigour subscale and the EORTC QLQ-C30 role func-
tioning domain (r = 0.394). As expected, total and
subscale scores of MFSI-SF were moderately corre-
lated (|r| = 0.451 to 0.655) to EORTC QLQ-C30 fa-
tigue symptom scale.
Further subgroup analysis was done based on the two
language versions (Additional file 1: Table S1). Results
obtained were largely similar as when results are pooled.
However, a moderate correlation (r = 0.451) was ob-
tained between MFSI-SF vigour subscale and EORTC
QLQ C-30 role functioning domain for the English ver-
sion while a poor correlation (r = 0.316) was obtained for
the Chinese version. Likewise, a moderate correlation (r
= 0.440) was obtained between total MFSI-SF score and
EORTC QLQ-C30 dyspnoea items score for the English
version while a poor correlation (r = 0.386) was obtained
for the Chinese version. In addition, a poor correlation
(r = 0.390) was observed between MFSI-SF mental sub-
scale and EORTC QLQ-C30 fatigue symptom scale for
the English version.
With regards to divergent validity, the total and
subscale scores of the MFSI-SF were poorly corre-
lated (|r| = 0.034 to 0.348) to the constipation and
diarrhoea items as expected. Similar results were ob-
tained in the subgroup analysis based on MFSI-SF
language version (Table 2 and Additional file 1:
Table S1).
Raw mean scores showed that total and subscale
MFSI-SF scores were in line with hypotheses for the
known groups (Table 3). Higher MFSI-SF scores were
obtained for those with more advanced cancer staging
and higher pain, depression and insomnia status.
Clinically significant differences were observed in
total MFSI-SF scores (score difference ≥ 10 points) of
patients with different depression, insomnia and pain
status. These differences were also statistically sig-
nificant (all p < 0.05). Amongst patients with differ-
ent cancer staging, the general and physical fatigue
subscales showed statistically significant differences
in scores.
Reliability
Results showed satisfactory internal consistency (α =
0.749 to 0.944) and acceptable item-to-subscale correla-
tions (r = 0.450 to 0.868) for both the English and Chin-
ese versions individually and when the results were
pooled for both versions (Table 4). Although all α values
were satisfactory, lower internal consistency was
observed across all domains for the Chinese version as
compared to the English version (α =0.749 to 0.917 vs
0.889 to 0.944).
Responsiveness
Data from 224 (91.1% among total participants) pa-
tients were obtained at T2. Correlation coefficients
for responsiveness can be found in Table 5. Poor cor-
relations were observed between change in total
MFSI-SF scores and change in EORTC QLQ-C30 pain
symptom scale and dyspnoea and insomnia item score
(|r| = 0.240 to 0.349). A moderate correlation was ob-
served between change in total MFSI-SF score and
change in EORTC QLQ-C30 fatigue symptom scale
and global QoL scale (r = 0.478 and − 0.404 respect-
ively) as hypothesised. For the change in MFSI-SF
subscale scores, poor correlations were observed be-
tween all hypothesised correlated EORTC QLQ-C30
subscales (|r| = 0.202 to 0.361) except for a moderate
correlation between change in MFSI-SF emotional fa-
tigue subscale score and change in EORTC QLQ-C30
emotional functioning score. Change in total and sub-
scale scores on MFSI-SF were poorly correlated (|r| =
0.005 to 0.185) with change in constipation and diar-
rhoea item scores as expected.
Based on the pre-defined clinically significant score
differences (score difference ≥ 10 points), there were no
clinically significant score differences observed for
change in total and MFSI-SF subscale scores between T1
and T2 (Additional file 1: Table S2).
Measurement equivalence
All statistically significant different variables between the
Chinese and English populations obtained from Table 1
and Additional file 1: Table S3, except for menopausal
status, were adjusted in the regression model when
evaluating the measurement equivalence between the
English and Chinese versions of MFSI-SF (Table 6 and
Additional file 1: Table S4). Menopausal status was not
included in the model as it is associated to differences in
age, which was already adjusted for in the regression
model. Ten patients (4.1%) with missing values for the
variables adjusted were excluded from measurement
equivalence analysis. Ultimately, 236 patients (95.9%)
were included into the analysis. After adjusting for the
covariates, the 95% CI for the adjusted difference of the
general, physical, mental subscales and total MFSI-SF
scores between the English and Chinese versions of
MFSI-SF were within the ±0.5 S.D. margin, suggesting
an acceptable measurement equivalence between the
two language versions. However, the 95% CI of the ad-
justed difference between the English and Chinese ver-
sions for the emotional and vigour subscale exceeded
the ±0.5 S.D. margin.
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Table 4 Internal consistency of the MFSI-SF subscales and the corrected item-to-domain Spearman’s correlations
Domain/
Scale
Item Content
(Listed in English)
Total MFSI-SF score of
English and Chinese
versions (N = 246)
English version
of MFSI-SF (n = 160)
Chinese version of
MFSI-SF (n = 86)
Corrected item-to-domain
correlationa
Cronbach’s
α
Corrected item-to-domain
correlation
Cronbach’s
α
Corrected item-to-domain
correlation
Cronbach’s
α
General
(6 items)
0.914 0.917 0.904
10 I feel pooped 0.611 0.530 0.765
12 I feel worn out 0.726 0.694 0.778
14 I feel fatigued 0.758 0.769 0.715
17 I feel sluggish 0.624 0.686 0.474
18 I feel run down 0.732 0.761 0.747
28 I feel tired 0.773 0.751 0.783
Physical
(6 items)
0.863 0.889 0.749
2 My muscles ache 0.614 0.685 0.463
4 My legs feel weak 0.616 0.676 0.479
6 My head feels heavy 0.477 0.491 0.450
16 My arms feel weak 0.568 0.608 0.503
19 I ache all over 0.632 0.702 0.476
26 My body feels heavy all
over
0.629 0.686 0.502
Emotional
(6 items)
0.912 0.921 0.887
3 I feel upset 0.746 0.737 0.764
8 I feel nervous 0.676 0.699 0.632
13 I feel sad 0.789 0.789 0.787
21 I feel depressed 0.723 0.720 0.727
23 I feel tense 0.685 0.732 0.600
30 I am distressed 0.678 0.655 0.730
Mental
(6 items)
0.921 0.928 0.889
1 I have trouble
remembering things
0.748 0.784 0.674
11 I am confused 0.615 0.622 0.603
15 I have trouble paying
attention
0.729 0.780 0.635
20 I am unable to
concentrate
0.716 0.740 0.671
25 I make more mistakes
than usual
0.679 0.671 0.701
27 I am forgetful 0.781 0.798 0.756
Vigour
(6 items)
0.936 0.944 0.917
5 I feel cheerful 0.833 0.827 0.844
7 I feel lively 0.820 0.868 0.719
9 I feel relaxed 0.790 0.839 0.690
22 I feel refreshed 0.833 0.829 0.843
24 I feel energetic 0.853 0.853 0.862
29 I feel calm 0.803 0.833 0.749
All correlations were significant at the 0.01 level (two tailed)
All Cronbach’s alpha coefficient was above the satisfactory level of 0.7
All items had satisfactory item-to-domain correlation (defined by a corrected r > 0.300)
MFSI-SF Multidimensional Fatigue Symptom Inventory - Short Form
aThe corrected item-to-domain correlation was calculated for each item by removing the contribution of the item’s score to its corresponding subscale score
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Discussion
This study suggests that MFSI-SF has a reasonably
satisfactory validity with good internal consistency for
use in the local multi-ethnic cancer population in
Singapore. This is in line with overseas validation
studies of MFSI-SF which demonstrated the validity
and reliability of MFSI-SF using other references for
construct validity such as STAI (State-Trait Anxiety
Inventory for Adults) [4, 37]. However, MFSI-SF may
not be responsive to the changes in fatigue level
Table 5 Spearman’s correlations between change in scores on the MFSI-SF subscales and EORTC QLQ-C30 domains
EORTC QLQ-C30 MFSI-SF
General Fatigue Physical Fatigue Emotional Fatigue Mental Fatigue Vigour Total Score
Functional
Physical − 0.292a − 0.239a − 0.156b − 0.173a 0.183a − 0.297a
Role − 0.262a − 0.202a − 0.211a − 0.203a 0.202a − 0.296a
Emotional − 0.236a − 0.241a − 0.447a − 0.243a 0.219a − 0.372a
Cognitive − 0.202a − 0.205a − 0.196a − 0.361a 0.183a − 0.294a
Social − 0.231a − 0.153a − 0.180a − 0.124 0.156b − 0.228a
Global QOL
Global health status (GHS) − 0.361a − 0.286a − 0.317 − 0.180a 0.302a − 0.404a
Symptom scales
Fatigue 0.412 0.368a 0.406a 0.277a − 0.283a 0.478a
Pain 0.221 0.350a 0.113 0.127 − 0.090 0.240a
Symptom Items
Dyspnoea 0.170b 0.275a 0.302a 0.226a − 0.187a 0.286a
Insomnia 0.266a 0.309a 0.191a 0.200a − 0.242a 0.349a
Appetite loss 0.230a 0.210a 0.277a 0.194a − 0.345a 0.354a
Constipation 0.099 0.063 0.083 0.006 − 0.185a 0.114
Nausea & vomiting 0.089 0.076 0.127 0.163b − 0.139b 0.159b
Diarrhoea 0.098 0.153b − 0.046 − 0.079 0.005 0.029
Financial Difficulties 0.132b 0.095 0.141 0.143b − 0.267a 0.225a
MFSI-SF Multidimensional Fatigue Symptom Inventory - Short Form, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life
Core Questionnaire 30
Unmarked correlations were not significant at the 0.05 level
aCorrelation was significant at the 0.01 level (2-tailed)
bCorrelation was significant at the 0.05 level (2-tailed)
Bolded values indicate hypothesised correlations
Table 6 Total and subscale score of English and Chinese MFSI-SF versions and measurement equivalence between the two versions
(Theoretical
Score Range)
Mean ± S.D. English vs. Chinese
Total
(N = 236)e
English-version
(n = 155)
Chinese-version
(n = 81)
Equivalence margina
(±0.25 S.D.)
Equivalence marginb
(±0.5 S.D.)
95% CI of
Unadjusted
difference
95% CI of
Adjusted
differencec
Total MFSI-SF score 0.720 (19.06) 1.56 (20.32) − 0.889 (16.36) ± 4.59 ± 9.17 − 2.450 (− 7.599 to 2.698) 0.095 (− 1.512 to 0.097)
General 4.34 (4.51) 4.87 (4.74) 3.33 (3.84) ± 1.07 ± 2.15 − 1.538 (− 2.742 to − 0.333) − 0.009 (− 1.327 to 1.148)
Physical 3.88 (4.11) 4.22 (4.51) 3.22 (3.15) ± 0.96 ± 1.91 − 0.997 (− 2.103 to 0.109) 0.023 (− 0.967 to 1.357)
Emotional 3.21 (4.25) 3.34 (4.46) 2.96 (3.83) ± 1.04 ± 2.07 − 0.373 (− 1.522 to 0.777) 0.096 (− 0.423 to 2.142)d
Mental 3.00 (3.91) 3.32 (4.28) 2.38 (3.01) ± 0.91 ± 1.82 − 0.933 (− 1.985 to 0.118) − 0.016 (− 1.274 to 1.017)
Vigour 13.70 (6.48) 13.18 (6.61) 12.79 (6.14) ± 1.59 ±3.19 − 1.391 (− 3.134 to 0.353) − 0.217 (− 4.922 to − 0.991)d
MFSI-SF Multidimensional Fatigue Symptom Inventory - Short Form
Equivalence was assessed by comparing 95% CI of the adjusted difference to the equivalence margin (±0.5 S.D.)
aThe equivalence margin is the simple average of the standard deviation of the Chinese and English scores multiplied by 0.25
bThe equivalence margin is the simple average of the standard deviation of the Chinese and English scores multiplied by 0.50
cMean difference between the English and Chinese version was adjusted for relevant variables that showed statistical significant differences between the English
and Chinese version of MFSI-SF (Table 1 and Additional file 1: Table S3): age, race (Chinese vs Non-Chinese), education (low education vs high education), ECOG
status, EORTC nausea and vomiting symptom, EORTC dyspnoea item
d95% CI of the adjusted difference exceeded the equivalence margin threshold (±0.5 S.D.)
eData for ECOG was missing for 10 patients
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following consecutive cycles of chemotherapy in this
patient population. Measurement equivalence for the
English and Chinese version was demonstrated for
total MFSI-SF score based on the equivalence margin
of ±0.5 S.D. However, pooled results obtained from
the individual subscales of MFSI-SF should be inter-
preted with caution as measurement equivalences
were not obtained for the emotional and vigour
subscales.
For construct validity, poor correlation was observed
between MFSI-SF vigour subscale and EORTC QLQ C-
30 role functioning subscale. On further analyses based
on language version, the poor correlation was only ob-
served in the Chinese version of MFSI-SF. This could be
attributed to poor equivalence between the English and
Chinese version of the MFSI-SF vigour subscale which
has also been reflected in the measurement equivalence
analysis. Hence, pooled results from the vigour subscale
should be interpreted cautiously and further modifica-
tions should be made to the Chinese version of MFSI-SF
vigour subscale to improve equivalence.
For known group validity, higher fatigue scores were
obtained for patients with more advanced cancer staging
as well as more depression, insomnia and pain symp-
toms. However, only total MFSI-SF scores showed clinic-
ally significant differences between patients with
different depression, insomnia and pain status. The in-
ability to observe a clinically significant difference
amongst patients with different cancer staging might be
due to majority of patients being in stage II (54.5%) and
stage III of cancer (20.3%). The difference between fa-
tigue levels of patients in stages II and III might not be
as large. Hence, clinically significant difference might
not be observable when the scores are pooled with pa-
tients in stages I and IV respectively. Furthermore, as
the MCID established was based on total MFSI-SF
scores, it may not be as appropriate when extrapolating
to clinical significance of subscale scores. This might
have also contributed to the lack of clinical significance
observed for most of the subscales.
MFSI-SF has also demonstrated good internal
consistency in this study. This is in line with previ-
ous validation studies conducted in the United States
for the English version of MFSI-SF and the Chinese
version of MFSI-SF in Taiwan which obtained α > 0.7
[5, 6]. However, item 17 in the Chinese version used
in this study showed a moderate item-to-domain cor-
relation as compared to the high correlations ob-
served for other items in the scale (r = 0.474). It may
appear that literal equivalence is achieved with the
translation, but there might be issues associated with
cultural equivalence with the translation [38]. This
could possibly explain the different interpretations of
item 17 in the Chinese version and hence, the lower
item-to-domain correlation. In the English version of
MFSI-SF, a moderate correlation was observed for
item 10 “I feel pooped” (r = 0.530) as compared to
the high item-to-domain correlation for the Chinese
version (r = 0.765). During data collection, researchers
were often asked by patients to explain the meaning
of “pooped” as they did not understand the term.
MFSI-SF was developed in the United States and is-
sues associated with cross cultural adaptation of the
instrument might possibly explain the inability to in-
terpret slang terms like “pooped” [39]. Furthermore,
the relatively older patient population of this study
(53.4 ± 10.0 years old) might further contribute to
lower understanding of slang words as they might
not be as exposed to foreign culture via popular
media as compared to the younger population. All
these could result in the lower item-to-domain cor-
relation. As such, possible modifications to item 10
and item 17 could be done to improve the psycho-
metric properties of the tool.
Responsiveness of a QoL tool can affect its ability
to assess the effectiveness of treatment strategies or
be used as a primary outcome measure to detect
changes in clinical trials. Total MFSI-SF score could
detect changes in patient’s fatigue levels and global
QoL score. However, the ability of individual sub-
scales of MFSI-SF to detect the magnitude of
changes in relevant constructs were not as expected.
The hypothesised magnitude of correlation was only
observed between change in MFSI-SF emotional sub-
scale score and change in EORTC QLQ-C30 emo-
tional functioning score. As a group, there was also a
lack of clinically significant change observed amongst
patients between T1 and T2. The poor responsive-
ness could be partly attributed to the generally lower
mean scores obtained across subscale and total
MFSI-SF scores at T1 and T2 (score ranges from 0
to 24 for individual subscales and − 24 to 96 for total
MFSI-SF score). During data collection, patients tend
to be more conservative in choosing extreme score
ranges which might have contributed to the lower
mean scores obtained. Such low scores were more
evident in the Chinese population (Additional file 1:
Table S4). This could be reflective of a true fatigue
level of our population, or this could possibly be due
to certain underlying values with regards to reporting
of “negative” symptoms experienced. This was evi-
dent with the EORTC QLQ-C30 scores obtained in
this study, where lower scores were obtained for
more subjective “negative” attributes (e.g. fatigue,
pain) while “positive” attributes such as functioning
had higher scores observed. The lower scores ob-
tained might have resulted in a floor effect whereby
further deterioration in fatigue scores following
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consecutive cycles of chemotherapy would not be
clinically observable.
Measurement equivalence was not observed for the
emotional and vigour subscales. This is possibly attrib-
uted to translation errors or differences in cultural inter-
pretation for these items. Items in the emotional and
vigour subscale involved asking patients on how they are
feeling. Different levels of tolerance towards self-
expression between the Chinese and Western culture
could possibly explain for these differences, leading to a
more conservative response in the Chinese version of
the questionnaire as mentioned above. Hence, caution
must be exercised when interpreting pooled results from
these subscales.
There are several limitations to this study. Firstly, a de-
tailed cognitive briefing of both language versions of
MFSI-SF was not performed. However, the English ver-
sion was heavily used and validated in numerous studies,
and we had piloted the Chinese version with a few pa-
tients to ensure there is no ambiguity with the language.
Secondly, factor analyses were not conducted for MFSI-
SF [40]. Factor analysis is a form of construct validation
and helps to explore patterns of correlations between
items or for confirming the pre-existing factor structure
of MFSI-SF. Factor analyses were not conducted due to
limited sample size of our study. COSMIN checklist rec-
ommends a minimum subject-to-variable ratio of 4:1 for
factor analyses [41]. Our sample size (n = 86) for the
Chinese version would be inadequate for factor analyses
with the 30-item MFSI-SF questionnaire [41]. However,
previous validation study done in Taiwan on a Chinese
version of MFSI-SF supports a four subscale structure of
physical, emotional, mental and vigour subscale instead
[6]. Furthermore, problematic items were also observed
in the general subscale based on item-to-domain cor-
relations analyses and discrepancies in the correlation
between the MFSI-SF vigour subscale and EORTC
QLQ-C30 role functioning domain was also observed
following subgroup analyses based on language ver-
sion. Hence, future validation studies can consider
recruiting a larger sample size for Exploratory Factor
Analysis (EFA) and Confirmatory Factor Analysis
(CFA) on the Chinese version of MFSI-SF. Thirdly,
the instrument used for construct validation is a
HRQoL measure rather than a fatigue measure. Al-
though QoL and fatigue are closely related constructs,
there are still fundamental differences in their inter-
pretation. This could potentially limit the conclusions
drawn from this study. However, given that there is a
lack of cancer-related fatigue questionnaires validated
in the Singaporean cancer population and EORTC
QLQ-C30 has been well-validated and utilised in this
cancer population, EORTC QLQ-C30 was chosen as
the comparator instrument for construct validation.
Fourthly, responsiveness analyses were based on hy-
pothesis testing rather than using a gold standard for
comparison. As the criterion approach will provide
stronger evidence for responsiveness of MFSI-SF, fu-
ture studies can consider using a gold standard such
as a global rating scale to evaluate changes in the fa-
tigue levels. Lastly, MFSI-SF uses a five point Likert
scale respond format. Classical test theory for evaluat-
ing psychometric properties assumes an interval or
even ratio measurement between these responses [42].
However, the relative value between each option
might not be equivalent. Hence, more sophisticated
psychometric tests such as Rasch analysis based on
Item Response Theory (IRT) could be done in future
validation studies to evaluate how specific test item
functions in MFSI-SF.
Ever since its development, MFSI-SF has been exten-
sively used as a fatigue assessment tool in studies. Fa-
tigue levels in both cancer and non-cancer patient
population were assessed using MFSI-SF and demon-
strated good reliability and validity [37]. Coupled with
results from this study, there is a potential for the clin-
ical utility of MFSI-SF as a fatigue assessment tool in
local studies and could possibly be validated in non-
cancer population in the future.
Conclusion
MFSI-SF is a reasonably valid instrument with good
internal consistency in assessing patient’s fatigue level
among breast cancer and lymphoma patients in
Singapore. MFSI-SF’s ability to detect changes in fa-
tigue level following multiple cycles of chemotherapy
remains uncertain. However, if needed, total MFSI-SF
score rather than individual subscale score should be
used to detect changes in patient’s fatigue level. The
English and Chinese versions of MFSI-SF also dem-
onstrated comparable equivalence but measurement
equivalence was uncertain for the emotional and
vigor subscales. Thus, one should be more mindful
when interpreting results pooled from these two
subscales.
Endnotes
1ECOG Status is a functional scale developed by the
Eastern Cooperative Oncology Group in 1982. It serves
as a measure of how a disease impacts a patient’s daily
living abilities and describes a patient’s level of function-
ing in terms of their ability to care for themselves, daily
activity, and physical ability. 0 corresponds to a patient
who is fully active and able to carry out performance
without restriction to 5 which represents that the patient
is dead [8].
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